{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:35:34Z","timestamp":1748910934318},"reference-count":0,"publisher":"Akademiai Kiado Zrt.","issue":"26","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["Orv Hetil."],"published-print":{"date-parts":[[2020,6]]},"abstract":"Absztrakt: <\/jats:title>\n Bevezet\u00e9s:<\/jats:italic> Az antraciklinkezel\u00e9shez kapcsol\u00f3d\u00f3 sz\u00edvel\u00e9gtelens\u00e9g\n kialakul\u00e1s\u00e1t jelent\u0151sen befoly\u00e1solja az alkalmazott kumulat\u00edv d\u00f3zis. Kor\u00e1bban\n publik\u00e1lt adatok szerint doxorubicin eset\u00e9n, 450 mg\/m2<\/jats:sup> alatti\n kumulat\u00edv d\u00f3zis mellett, alacsony a sz\u00edvel\u00e9gtelens\u00e9g kialakul\u00e1s\u00e1nak rizik\u00f3ja.\n Mivel a jelenlegi gyakorlatban a doxorubicinter\u00e1pia sor\u00e1n \u00e1ltal\u00e1ban nem \u00e9rik el\n ezt a d\u00f3zist, a kezel\u00e9s k\u00f6vetkezt\u00e9ben kialakul\u00f3 sz\u00edvel\u00e9gtelens\u00e9g kiv\u00e1lt\u00e1s\u00e1ban\n egy\u00e9b t\u00e9nyez\u0151k j\u00e1tszanak jelent\u0151s szerepet. C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> C\u00e9lunk\n a jelenlegi gyakorlat szerint alkalmazott doxorubicinkezel\u00e9shez kapcsol\u00f3d\u00f3\n sz\u00edvel\u00e9gtelens\u00e9g rizik\u00f3t\u00e9nyez\u0151inek r\u00e9szletes felt\u00e1r\u00e1sa volt.\n M\u00f3dszer:<\/jats:italic> A hazai eg\u00e9szs\u00e9g\u00fcgyi finansz\u00edroz\u00e1si adatb\u00e1zisok \u00e9s\n a Nemzeti R\u00e1kregiszter adatainak felhaszn\u00e1l\u00e1s\u00e1val retrospekt\u00edv elemz\u00e9st\n v\u00e9gezt\u00fcnk, melybe azokat a betegeket vontuk be, akikn\u00e9l 2004 \u00e9s 2015 k\u00f6z\u00f6tt\n eml\u0151daganat igazol\u00f3dott sz\u00f6vettani vizsg\u00e1lattal. Kiz\u00e1r\u00f3lag azokat a betegeket\n elemezt\u00fck, akikn\u00e9l a k\u00f3rel\u0151zm\u00e9nyben nem szerepelt kemoter\u00e1pia vagy\n sz\u00edvel\u00e9gtelens\u00e9gre utal\u00f3 adat a daganat igazol\u00f3d\u00e1sa el\u0151tt. A sz\u00edvel\u00e9gtelens\u00e9gi\n v\u00e9gpontot az I50-es diagn\u00f3zisk\u00f3dnak a fekv\u0151beteg- vagy a boncol\u00e1si dokumentumban\n val\u00f3 megjelen\u00e9s\u00e9vel defini\u00e1ltuk. Statisztikai anal\u00edzis:<\/jats:italic> A\n sz\u00edvel\u00e9gtelens\u00e9g kialakul\u00e1s\u00e1nak es\u00e9ly\u00e9t befoly\u00e1sol\u00f3 t\u00e9nyez\u0151ket t\u00f6bbv\u00e1ltoz\u00f3s\n bin\u00e1ris logisztikus regresszi\u00f3 alkalmaz\u00e1s\u00e1val azonos\u00edtottuk. A t\u00e1rsbetegs\u00e9gek \u00e9s\n a demogr\u00e1fiai adatok mellett az onkol\u00f3giai st\u00e1diumot \u00e9s az onkol\u00f3giai kezel\u00e9sek\n kumulat\u00edv d\u00f3zisait is figyelembe vett\u00fck az elemz\u00e9sben.\n Eredm\u00e9nyek:<\/jats:italic> A 3288, doxorubicinnel kezelt betegn\u00e9l a\n sz\u00edvel\u00e9gtelens\u00e9gi v\u00e9gpont kumulat\u00edv incidenci\u00e1ja 6,2%-nak ad\u00f3dott. A\n sz\u00edvel\u00e9gtelens\u00e9g el\u0151fordul\u00e1sa fokoz\u00f3dott 400 mg\/m2<\/jats:sup> f\u00f6l\u00f6tti\n doxorubicin kumulat\u00edv d\u00f3zis eset\u00e9n. Nagym\u00e9rt\u00e9kben n\u0151tt a rizik\u00f3 az \u00e9letkor\n el\u0151rehaladt\u00e1val is, m\u00e1r 50 \u00e9v felett szignifik\u00e1ns kock\u00e1zatn\u00f6veked\u00e9s volt\n megfigyelhet\u0151. Emellett magasabb rizik\u00f3val kapcsol\u00f3dott a cukorbetegs\u00e9g, a\n pirimidinanal\u00f3gok, a karboplatin (platinaalap\u00fa szer) \u00e9s a bevacizumab jelenl\u00e9te.\n K\u00f6vetkeztet\u00e9s:<\/jats:italic> A hazai finansz\u00edroz\u00e1si adatb\u00e1zisok \u00e9s a\n R\u00e1kregiszter adatb\u00e1zis\u00e1nak integr\u00e1lt elemz\u00e9se r\u00e9v\u00e9n a jelenlegi gyakorlatnak\n megfelel\u0151en alkalmazott doxorubicinkezel\u00e9shez kapcsol\u00f3d\u00f3 sz\u00edvel\u00e9gtelens\u00e9g\n rizik\u00f3t\u00e9nyez\u0151i popul\u00e1ci\u00f3szinten azonos\u00edthat\u00f3k voltak. Orv Hetil. 2020; 161(26):\n 1094\u20131102.<\/jats:p>","DOI":"10.1556\/650.2020.31739","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T01:01:40Z","timestamp":1595984500000},"page":"1094-1102","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":5,"title":["A doxorubicinkezel\u00e9shez kapcsol\u00f3d\u00f3 sz\u00edvel\u00e9gtelens\u00e9g kialakul\u00e1s\u00e1nak rizik\u00f3t\u00e9nyez\u0151i a hazai orsz\u00e1gos adatb\u00e1zisok integr\u00e1lt, retrospekt\u00edv elemz\u00e9se alapj\u00e1n"],"prefix":"10.1556","volume":"161","author":[{"given":"Gy\u00f6rgy","family":"Fogarassy","sequence":"first","affiliation":[{"name":"1 \u00c1llami Sz\u00edvk\u00f3rh\u00e1z Balatonf\u00fcred, Gy\u00f3gy t\u00e9r 2., 8230"},{"name":"2 \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai Orvostudom\u00e1nyi Doktori Iskola, Szegedi Tudom\u00e1nyegyetem Szeged"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"Fogarassyn\u00e9 Vathy","sequence":"additional","affiliation":[{"name":"3 Rendszer- \u00e9s Sz\u00e1m\u00edt\u00e1studom\u00e1nyi Tansz\u00e9k, Pannon Egyetem Veszpr\u00e9m"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Kov\u00e1ts","sequence":"additional","affiliation":[{"name":"4 \u00c1llami Eg\u00e9szs\u00e9g\u00fcgyi Ell\u00e1t\u00f3 K\u00f6zpont Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"Horny\u00e1k","sequence":"additional","affiliation":[{"name":"5 Onkol\u00f3giai Centrum, Csolnoky Ferenc K\u00f3rh\u00e1z Veszpr\u00e9m"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"Kenessey","sequence":"additional","affiliation":[{"name":"6 Nemzeti R\u00e1kregiszter \u00e9s Biostatisztikai K\u00f6zpont, Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zet Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Veress","sequence":"additional","affiliation":[{"name":"1 \u00c1llami Sz\u00edvk\u00f3rh\u00e1z Balatonf\u00fcred, Gy\u00f3gy t\u00e9r 2., 8230"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba","family":"Polg\u00e1r","sequence":"additional","affiliation":[{"name":"7 Sug\u00e1rter\u00e1pi\u00e1s K\u00f6zpont, Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zet Budapest"},{"name":"8 \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Onkol\u00f3giai Tansz\u00e9k, Semmelweis Egyetem Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Forster","sequence":"additional","affiliation":[{"name":"9 \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, II. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Kardiol\u00f3giai K\u00f6zpont, Szegedi Tudom\u00e1nyegyetem Szeged"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/161\/26\/article-p1094.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/161\/26\/article-p1094.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T01:13:34Z","timestamp":1633914814000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/161\/26\/article-p1094.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":0,"journal-issue":{"issue":"26"},"URL":"https:\/\/doi.org\/10.1556\/650.2020.31739","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}